Physician profile
Mal R Homan
NPI 1215905898
$1,069.34
in general payments reported to CMS, 2019-2025
10 companies · $17.37 in 2025
The $17.37 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $213 · 2021: $125 · 2022: $101 · 2023: $129 · 2024: $17.21 · 2025: $17.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $163.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $249.60 | 2019-2021 | |
| Amgen INC. | $218.39 | 2019-2023 | |
| Tandem Diabetes Care, INC. | $181.53 | 2019-2020 | |
| Novo Nordisk INC | $138.91 | 2019-2020 | |
| Genzyme Corporation | $110.00 | 2019 | |
| Abbott Laboratories | $46.34 | 2022-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $37.20 | 2022 | |
| Vifor Pharma, INC. | $34.58 | 2024-2025 | Veltassa |
| Alexion Pharmaceuticals, INC. | $34.31 | 2022 | |
| Amryt Pharma Holdings LTD | $18.48 | 2023 | Mycapssa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mal Homan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.